Health and Healthcare

What to Expect From Baxalta Q4 Earnings

Trey Thoelcke

Published: February 15, 2016 9:45 am

Last Updated: January 13, 2020 1:11 pm

Baxalta Inc. (NYSE: BXLT) is scheduled to report fourth-quarter and full-year results before markets open on Tuesday. The hematology and immunology focused biopharmaceutical company is expected to post earnings per share (EPS) of $0.56 and revenues of $1.71 billion for the quarter, as well as full-year EPS of $2.07 on revenues of $6.17 billion.

Baxalta, which was spun out of Baxter International Inc. (NYSE: BAX) last July, reported per-share earnings of $0.56 back in the third quarter, which handily exceeded analysts’ expectations. Guidance at the time called for EPS of $0.55 to $0.57 for the fourth quarter.

The big news for Baxalta is that last month it finally agreed to merge with U.K.-based Shire PLC (NASDAQ: SHPG) in a deal worth around $32 billion. Shire first made a bid for Baxalta on August 4, but Baxalta said that bid was too low. The deal now is expected to close in mid-2016.

Back in December of 2015, Baxalta announced it had received a key U.S. Food and Drug Administration (FDA) approval for its drug that treats von Willebrand disease, a rare inherited bleeding disorder that results from a missing protein. The company plans to launch the drug under the brand name Vonvendi, expanding its portfolio of treatments for bleeding disorders, led by the hemophilia treatments Advate and Feiba.

24/7 Wall St.
6 Biotech and Pharma Stocks Analysts Want You to Buy Now